{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T05:46:40Z","timestamp":1788068800378,"version":"build-2784847793"},"reference-count":87,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T00:00:00Z","timestamp":1675468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Chronic lung infections in cystic fibrosis (CF) patients are triggered by multidrug-resistant bacteria such as Pseudomonas aeruginosa, Achromobacter xylosoxidans, and Stenotrophomonas maltophilia. The CF airways are considered ideal sites for the colonization and growth of bacteria and fungi that favor the formation of mixed biofilms that are difficult to treat. The inefficacy of traditional antibiotics reinforces the need to find novel molecules able to fight these chronic infections. Antimicrobial peptides (AMPs) represent a promising alternative for their antimicrobial, anti-inflammatory, and immunomodulatory activities. We developed a more serum-stable version of the peptide WMR (WMR-4) and investigated its ability to inhibit and eradicate C. albicans, S. maltophilia, and A. xylosoxidans biofilms in both in vitro and in vivo studies. Our results suggest that the peptide is able better to inhibit than to eradicate both mono and dual-species biofilms, which is further confirmed by the downregulation of some genes involved in biofilm formation or in quorum-sensing signaling. Biophysical data help to elucidate its mode of action, showing a strong interaction of WMR-4 with lipopolysaccharide (LPS) and its insertion in liposomes mimicking Gram-negative and Candida membranes. Our results support the promising therapeutic application of AMPs in the treatment of mono- and dual-species biofilms during chronic infections in CF patients.<\/jats:p>","DOI":"10.3390\/ijms24043092","type":"journal-article","created":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T02:57:32Z","timestamp":1675652252000},"page":"3092","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Myxinidin-Derived Peptide against Biofilms Caused by Cystic Fibrosis Emerging Pathogens"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2163-5163","authenticated-orcid":false,"given":"Rosa","family":"Bellavita","sequence":"first","affiliation":[{"name":"Department of Pharmacy, School of Medicine, University of Naples \u2018Federico II\u2019, Via Domenico Montesano 49, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4981-8837","authenticated-orcid":false,"given":"Angela","family":"Maione","sequence":"additional","affiliation":[{"name":"Department of Biology, University of Naples \u2018Federico II\u2019, Via Cinthia, 80126 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Braccia","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, School of Medicine, University of Naples \u2018Federico II\u2019, Via Domenico Montesano 49, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marica","family":"Sinoca","sequence":"additional","affiliation":[{"name":"Department of Biology, University of Naples \u2018Federico II\u2019, Via Cinthia, 80126 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7849-7024","authenticated-orcid":false,"given":"Stefania","family":"Galdiero","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, School of Medicine, University of Naples \u2018Federico II\u2019, Via Domenico Montesano 49, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8116-0839","authenticated-orcid":false,"given":"Emilia","family":"Galdiero","sequence":"additional","affiliation":[{"name":"Department of Biology, University of Naples \u2018Federico II\u2019, Via Cinthia, 80126 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6538-8585","authenticated-orcid":false,"given":"Annarita","family":"Falanga","sequence":"additional","affiliation":[{"name":"Department of Agricultural Sciences, University of Naples \u2018Federico II\u2019, Via dell\u2019 Universit\u00e0 100, 80055 Portici, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"639475","DOI":"10.3389\/fphar.2021.639475","article-title":"Treatment of cystic fibrosis: From gene- to cell-based therapies","volume":"12","author":"Allan","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1183\/09031936.03.00057003","article-title":"New concepts of the pathogenesis of cystic fibrosis lung disease","volume":"23","author":"Boucher","year":"2004","journal-title":"Eur. Respir. J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrg3849","article-title":"Cystic fibrosis genetics: From molecular understanding to clinical application","volume":"16","author":"Cutting","year":"2015","journal-title":"Nat. Rev. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jcf.2007.06.006","article-title":"Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis","volume":"7","author":"Valenza","year":"2008","journal-title":"J. Cyst. Fibros."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"a009589","DOI":"10.1101\/cshperspect.a009589","article-title":"CFTR, mucins, and mucus obstruction in cystic fibrosis","volume":"2","author":"Kreda","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/MCP.0b013e32835f1afc","article-title":"Respiratory bacterial infections in cystic fibrosis","volume":"19","author":"Ciofu","year":"2013","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jcf.2015.03.003","article-title":"Inflammation in cystic fibrosis lung disease: Pathogenesis and therapy","volume":"14","author":"Cantin","year":"2015","journal-title":"J. Cyst. Fibros."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jcf.2018.08.014","article-title":"Defining antimicrobial resistance in cystic fibrosis","volume":"17","author":"Kidd","year":"2018","journal-title":"J. Cyst. Fibros."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"108782","DOI":"10.1016\/j.celrep.2021.108782","article-title":"Pseudomonas aeruginosa aggregates in cystic fibrosis sputum produce exopolysaccharides that likely impede current therapies","volume":"34","author":"Jennings","year":"2021","journal-title":"Cell Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1586\/17476348.2015.995640","article-title":"The problems of antibiotic resistance in cystic fibrosis and solutions","volume":"9","author":"Oliver","year":"2015","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0140-6736(14)61137-5","article-title":"Antimicrobial resistance in the respiratory microbiota of people with cystic fibrosis","volume":"384","author":"Sherrard","year":"2014","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1055\/s-0039-1698464","article-title":"Microbiology of cystic fibrosis airway disease","volume":"40","author":"Blanchard","year":"2019","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_13","unstructured":"Cystic Fibrosis Foundation (2021). Patient Registry 2020 Annual Data Report, Cystic Fibrosis Foundation. Available online: https:\/\/www.cff.org\/sites\/default\/files\/2021-11\/Patient-Registry-Annual-Data-Report.pdf."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Menetrey, Q., Sorlin, P., Jumas-Bilak, E., Chiron, R., Dupont, C., and Marchandin, H. (2021). Achromobacter xylosoxidans and Stenotrophomonas maltophilia: Emerging pathogens well-armed for life in the cystic fibrosis patients\u2019 lung. Genes, 12.","DOI":"10.3390\/genes12050610"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ijantimicag.2018.09.001","article-title":"Antimicrobial susceptibility of non-fermenting Gram-negative pathogens isolated from cystic fibrosis patients","volume":"53","author":"Ekkelenkamp","year":"2019","journal-title":"Int. J. Antimicrob. Agents."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e01025-20","DOI":"10.1128\/AAC.01025-20","article-title":"Achromobacter infections and treatment options","volume":"64","author":"Isler","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1128\/JCM.00814-12","article-title":"A multilocus sequence typing scheme implies population structure and reveals several putative novel Achromobacter species","volume":"50","author":"Spilker","year":"2012","journal-title":"J. Clin. Microbiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1513\/AnnalsATS.201406-288FR","article-title":"Achromobacter respiratory infections","volume":"12","author":"Swenson","year":"2015","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.resmic.2018.05.001","article-title":"Phage therapy against Achromobacter xylosoxidans lung infection in a patient with cystic fibrosis: A case report","volume":"169","author":"Hoyle","year":"2018","journal-title":"Res. Microbiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1097\/INF.0000000000000714","article-title":"Increased prevalence and resistance of important pathogens recovered from respiratory specimens of cystic fibrosis patients during a decade","volume":"34","author":"Raidt","year":"2015","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1017\/S0950268816001564","article-title":"Achromobacter xylosoxidans is the predominant Achromobacter species isolated from diverse non-respiratory samples","volume":"144","author":"Amoureux","year":"2016","journal-title":"Epidemiol. Infect."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1099\/jmm.0.000499","article-title":"Prevalence and species distribution of Achromobacter sp. cultured from cystic fibrosis patients attending the Aarhus centre in Denmark","volume":"66","author":"Gade","year":"2017","journal-title":"J. Med. Microbiol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Veschetti, L., Sandri, A., Krogh Johansen, H., Lle\u00f2, M.M., and Malerba, G. (2020). Hyper-mutation as an evolutionary mechanism for Achromobacter xylosoxidans in cystic fibrosis lung infection. Pathogens, 9.","DOI":"10.3390\/pathogens9020072"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jcf.2006.05.011","article-title":"Achromobacter xylosoxidans in cystic fibrosis: Prevalence and clinical relevance","volume":"6","author":"Schelstraete","year":"2007","journal-title":"J. Cyst. Fibros."},{"key":"ref_25","first-page":"CD009249","article-title":"Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis","volume":"7","author":"Amin","year":"2016","journal-title":"Cochrane Database Syst Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e00478-18","DOI":"10.1128\/JB.00478-18","article-title":"Cystic fibrosis-associated Stenotrophomonas maltophilia strain-specific adaptations and responses to pH","volume":"201","author":"Gallagher","year":"2019","journal-title":"J. Bacteriol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/thx.2003.017707","article-title":"Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis","volume":"59","author":"Goss","year":"2004","journal-title":"Thorax"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"15070","DOI":"10.1073\/pnas.0804326105","article-title":"A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients","volume":"105","author":"Sibley","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.2217\/fmb-2019-0200","article-title":"Recapitulation of polymicrobial communities associated with cystic fibrosis airway infections: A perspective","volume":"14","author":"Welch","year":"2019","journal-title":"Future Microbiol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Delhaes, L., Monchy, S., Fr\u00e9alle, E., Hubans, C., Salleron, J., Leroy, S., Prevotat, A., Wallet, F., Wallaert, B., and Dei-Cas, E. (2012). The airway microbiota in cystic fibrosis: A complex fungal and bacterial community-implications for therapeutic management. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0036313"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1378\/chest.09-2996","article-title":"Sputum Candida albicans presages FEV1 decline and hospital-treated exacerbations in cystic fibrosis","volume":"138","author":"Chotirmall","year":"2010","journal-title":"Chest"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/ppul.23302","article-title":"Association of chronic Candida albicans respiratory infection with a more severe lung disease in patients with cystic fibrosis","volume":"50","author":"Shoseyov","year":"2015","journal-title":"Pediatr. Pulmonol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s10096-019-03493-3","article-title":"Coexistence of Candida species and bacteria in patients with cystic fibrosis","volume":"38","author":"Haiko","year":"2019","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"200011","DOI":"10.1183\/16000617.0011-2020","article-title":"Coinfection with Pseudomonas aeruginosa and Aspergillus fumigatus in cystic fibrosis","volume":"29","author":"Keown","year":"2020","journal-title":"Eur. Respir. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Roscetto, E., Bellavita, R., Paolillo, R., Merlino, F., Molfetta, N., Grieco, P., Buommino, E., and Catania, M.R. (2021). Antimicrobial activity of a lipidated Temporin L analogue against carbapenemase-producing Klebsiella pneumoniae clinical isolates. Antibiotics, 10.","DOI":"10.3390\/antibiotics10111312"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Bellavita, R., Vollaro, A., Catania, M.R., Merlino, F., De Martino, L., Nocera, F.P., DellaGreca, M., Lembo, F., Grieco, P., and Buommino, E. (2020). Novel antimicrobial peptide from Temporin L in the treatment of Staphylococcus pseudintermedius and Malassezia pachydermatis in polymicrobial inter-kingdom infection. Antibiotics, 9.","DOI":"10.3390\/antibiotics9090530"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1128\/AAC.49.7.2921-2927.2005","article-title":"Antimicrobial peptide therapeutics for cystic fibrosis","volume":"49","author":"Zhang","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Luo, Y., and Song, Y. (2021). Mechanism of antimicrobial peptides: Antimicrobial, anti-inflammatory and antibiofilm activities. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222111401"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jcf.2003.12.008","article-title":"Beta-defensins and LL-37 in bronchoalveolar lavage fluid of patients with cystic fibrosis","volume":"3","author":"Chen","year":"2004","journal-title":"J. Cyst. Fibros."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"ftaa048","DOI":"10.1093\/femspd\/ftaa048","article-title":"Activity of airway antimicrobial peptides against cystic fibrosis pathogens","volume":"78","author":"Cabak","year":"2020","journal-title":"Pathog. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Martin, I., Waters, V., and Grasemann, H. (2021). Approaches to targeting bacterial biofilms in cystic fibrosis airways. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22042155"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"8548","DOI":"10.1038\/s41598-017-08361-8","article-title":"In vivo therapeutic efficacy of frog skin-derived peptides against Pseudomonas aeruginosa-induced pulmonary infection","volume":"7","author":"Chen","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00018-021-04030-2","article-title":"Esc peptides as novel potentiators of defective cystic fibrosis transmembrane conductance regulator: An unprecedented property of antimicrobial peptides","volume":"79","author":"Ferrera","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40121-013-0015-5","article-title":"The role of human beta-defensin-2 in Pseudomonas aeruginosa pulmonary infection in cystic fibrosis patients","volume":"2","author":"Dalcin","year":"2013","journal-title":"Infect. Dis. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1128\/AAC.00934-12","article-title":"Chimeric beta-defensin analogs, including the novel 3NI analog, display salt-resistant antimicrobial activity and lack toxicity in human epithelial cell lines","volume":"57","author":"Scudiero","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"9050","DOI":"10.1021\/acs.jmedchem.2c00270","article-title":"Antimicrobial peptides against multidrug-resistant Pseudomonas aeruginosa biofilm from cystic fibrosis patients","volume":"65","author":"Kapach","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41392-022-00904-4","article-title":"Therapeutic peptides: Current applications and future directions","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Del Genio, V., Bellavita, R., Falanga, A., Herv\u00e9-Aubert, K., Chourpa, I., and Galdiero, S. (2022). Peptides to overcome the limitations of current anticancer and antimicrobial nanotherapies. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14061235"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"563030","DOI":"10.3389\/fmicb.2020.563030","article-title":"D- and unnatural amino acid substituted antimicrobial peptides with improved proteolytic resistance and their proteolytic degradation characteristics","volume":"11","author":"Lu","year":"2020","journal-title":"Front. Microbiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"6720","DOI":"10.1039\/D1QO00892G","article-title":"Site-selective modification of peptide backbones","volume":"8","author":"Boto","year":"2021","journal-title":"Org. Chem. Front."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nchem.1062","article-title":"Contemporary strategies for peptide macrocyclization","volume":"3","author":"White","year":"2011","journal-title":"Nat. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"5665","DOI":"10.1128\/AAC.01341-13","article-title":"Structure-activity relations of myxinidin, an antibacterial peptide derived from the epidermal mucus of hagfish","volume":"57","author":"Cantisani","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Falanga, A., Maione, A., La Pietra, A., de Alteriis, E., Vitale, S., Bellavita, R., Carotenuto, R., Turr\u00e0, D., Galdiero, S., and Galdiero, E. (2022). Competitiveness during dual-species biofilm formation of Fusarium oxysporum and Candida albicans and a novel treatment strategy. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14061167"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Maione, A., Bellavita, R., de Alteriis, E., Galdiero, S., Albarano, L., La Pietra, A., Guida, M., Parrilli, E., D\u2019Angelo, C., and Galdiero, E. (2022). WMR peptide as antifungal and antibiofilm against albicans and non-albicans Candida species: Shreds of evidence on the mechanism of action. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23042151"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1271\/bbb.67.2269","article-title":"Effect of alpha, alpha-dialkyl amino acids on the protease resistance of peptides","volume":"67","author":"Yamaguchi","year":"2003","journal-title":"Biosci. Biotechnol. Biochem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/psc.876","article-title":"Design and synthesis of cationic Aib-containing antimicrobial peptides: Conformational and biological studies","volume":"13","author":"Zikou","year":"2007","journal-title":"J. Pept. Sci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1128\/EC.00279-10","article-title":"Candida albicans Als3, a multifunctional adhesin and invasin","volume":"10","author":"Liu","year":"2011","journal-title":"Eukaryot. Cell"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Kov\u00e1cs, R., and Majoros, L. (2020). Fungal Quorum-Sensing Molecules: A review of their antifungal effect against Candida biofilms. J. Fungi, 6.","DOI":"10.3390\/jof6030099"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jgar.2020.10.011","article-title":"Distribution of smf-1, rmlA, spgM and rpfF genes among Stenotrophomonas maltophilia isolates in relation to biofilm-forming capacity","volume":"23","author":"Azimi","year":"2020","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_60","first-page":"461","article-title":"Small protein-mediated quorum sensing in a gram-negative bacterium: Novel targets for control of infectious disease","volume":"12","author":"Ronald","year":"2011","journal-title":"Discov. Med."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Nielsen, S.M., Penstoft, L.N., and N\u00f8rskov-Lauritsen, N. (2019). Motility, biofilm formation and antimicrobial efflux of sessile and planktonic cells of Achromobacter xylosoxidans. Pathogens, 8.","DOI":"10.3390\/pathogens8010014"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1080\/21505594.2019.1621649","article-title":"Galleria mellonella as a consolidated in vivo model hosts: New developments in antibacterial strategies and novel drug testing","volume":"10","author":"Cutuli","year":"2019","journal-title":"Virulence"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"17795","DOI":"10.1038\/s41598-017-18102-6","article-title":"Structure and interactions of a host defense antimicrobial peptide Thanatin in lipopolysaccharide micelles reveal mechanism of bacterial cell agglutination","volume":"7","author":"Sinha","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1046\/j.1432-1033.2002.02963.x","article-title":"Tryptophan fluorescence study of the interaction of penetratin peptides with model membranes","volume":"269","author":"Christiaens","year":"2002","journal-title":"Eur. J. Biochem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ejmech.2017.11.030","article-title":"Urokinase receptor derived peptides as potent inhibitors of the formyl peptide receptor type 1-triggered cell migration","volume":"143","author":"Yousif","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Zannella, C., Chianese, A., Palomba, L., Marcocci, M.E., Bellavita, R., Merlino, F., Grieco, P., Folliero, V., De Filippis, A., and Mangoni, M. (2022). Broad-spectrum antiviral activity of the amphibian antimicrobial peptide Temporin L and its analogs. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23042060"},{"key":"ref_67","first-page":"M7-A7","article-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: Approved standard","volume":"26","author":"Wikler","year":"2006","journal-title":"CLSI"},{"key":"ref_68","unstructured":"Gerri, S.H. (2012). Interactions of Yeasts, Moulds, and Antifungal Agents: How to Detect Resistance, 2012 ed., Springer."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"11675","DOI":"10.1021\/acs.jmedchem.1c01033","article-title":"First-in-class cyclic Temporin L analogue: Design, synthesis, and antimicrobial assessment","volume":"64","author":"Bellavita","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0167-7012(00)00122-6","article-title":"A modified microtiter-plate test for quantification of staphylococcal biofilm formation","volume":"40","author":"Stepanovic","year":"2000","journal-title":"J. Microbiol. Methods"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/j.1600-0463.2007.apm_630.x","article-title":"Quantification of biofilm in microtiter plates: Overview of testing conditions and practical recommendations for assessment of biofilm production by staphylococci","volume":"115","author":"Stepanovic","year":"2007","journal-title":"APMIS"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Maione, A., La Pietra, A., de Alteriis, E., Mileo, A., De Falco, M., Guida, M., and Galdiero, E. (2022). Effect of myrtenol and its synergistic interactions with antimicrobial drugs in the inhibition of single and mixed biofilms of Candida auris and Klebsiella pneumoniae. Microorganisms, 10.","DOI":"10.3390\/microorganisms10091773"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Nielsen, S.M., Meyer, R.L., and N\u00f8rskov-Lauritsen, N. (2017). Differences in gene expression profiles between early and late isolates in monospecies Achromobacter biofilm. Pathogens, 6.","DOI":"10.3390\/pathogens6020020"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1093\/nar\/29.9.e45","article-title":"A new mathematical model for relative quantification in real-time RT-PCR","volume":"29","author":"Pfaffl","year":"2001","journal-title":"Nucleic Acids Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1093\/nar\/30.9.e36","article-title":"Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR","volume":"30","author":"Pfaffl","year":"2002","journal-title":"Nucleic Acids Res."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Maione, A., de Alteriis, E., Carraturo, F., Galdiero, S., Falanga, A., Guida, M., Di Cosmo, A., Maselli, V., and Galdiero, E. (2021). The membranotropic peptide gH625 to combat mixed Candida albicans\/Klebsiella pneumoniae biofilm: Correlation between in vitro anti-biofilm activity and in vivo antimicrobial protection. J. Fungi, 7.","DOI":"10.3390\/jof7010026"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Bellavita, R., Maione, A., Merlino, F., Siciliano, A., Dardano, P., De Stefano, L., Galdiero, S., Galdiero, E., Grieco, P., and Falanga, A. (2022). Antifungal and antibiofilm activity of cyclic Temporin L peptide analogues against albicans and non-albicans Candida species. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14020454"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"de Alteriis, E., Maione, A., Falanga, A., Bellavita, R., Galdiero, S., Albarano, L., Salvatore, M.M., Galdiero, E., and Guida, M. (2021). Activity of free and liposome-encapsulated essential oil from Lavandula angustifolia against persister-derived biofilm of Candida auris. Antibiotics, 11.","DOI":"10.3390\/antibiotics11010026"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1080\/14756366.2020.1819258","article-title":"Novel temporin L antimicrobial peptides: Promoting self-assembling by lipidic tags to tackle superbugs","volume":"35","author":"Bellavita","year":"2020","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1080\/14756366.2022.2134359","article-title":"Unveiling the mechanism of action of acylated temporin L analogues against multidrug-resistant Candida albicans","volume":"38","author":"Bellavita","year":"2023","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"6033","DOI":"10.1073\/pnas.0708354105","article-title":"Membrane damage by human islet amyloid polypeptide through fibril growth at the membrane","volume":"105","author":"Engel","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Del Genio, V., Falanga, A., Allard-Vannier, E., Herv\u00e9-Aubert, K., Leone, M., Bellavita, R., Uzbekov, R., Chourpa, I., and Galdiero, S. (2022). Design and validation of nanofibers made of self-assembled peptides to become multifunctional stimuli-sensitive nanovectors of anticancer drug doxorubicin. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14081544"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"160696","DOI":"10.1098\/rsos.160696","article-title":"Thioflavin T as an amyloid dye: Fibril quantification, optimal concentration and effect on aggregation","volume":"4","author":"Xue","year":"2017","journal-title":"R. Soc. Open. Sci."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0006-3495(95)80066-4","article-title":"Leakage of membrane vesicle contents: Determination of mechanism using fluorescence requenching","volume":"69","author":"Ladokhin","year":"1995","journal-title":"Biophys. J."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"8720","DOI":"10.1021\/bi00489a031","article-title":"Mechanism of leakage of phospholipid vesicle contents induced by the peptide GALA","volume":"29","author":"Parente","year":"1990","journal-title":"Biochemistry"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1751-1097.1989.tb09183.x","article-title":"Acrylamide quenching of tryptophan photochemistry and photophysics","volume":"49","author":"Tallmadge","year":"1989","journal-title":"Photochem. Photobiol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"8229","DOI":"10.1021\/bi00488a006","article-title":"The role of charge and hydrophobicity in peptide-lipid interaction: A comparative study based on tryptophan fluorescence measurements combined with the use of aqueous and hydrophobic quenchers","volume":"29","author":"Soekarjo","year":"1990","journal-title":"Biochemistry"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/4\/3092\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:24:25Z","timestamp":1760120665000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/4\/3092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,4]]},"references-count":87,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["ijms24043092"],"URL":"https:\/\/doi.org\/10.3390\/ijms24043092","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,4]]}}}